Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.
J Clin Microbiol
; 44(7): 2612-4, 2006 Jul.
Article
en En
| MEDLINE
| ID: mdl-16825395
ABSTRACT
We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Virología
/
VIH-1
/
Técnicas de Diagnóstico Molecular
/
Farmacorresistencia Viral
/
Mutación
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Evaluation_studies
Idioma:
En
Revista:
J Clin Microbiol
Año:
2006
Tipo del documento:
Article